AI Engines For more Details: Perplexity Kagi Labs You
Digestive Disorders: Some individuals with digestive disorders such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) may be sensitive to certain food additives, including SSL. While SSL is not typically associated with gastrointestinal symptoms, some individuals with digestive disorders may experience discomfort or exacerbation of symptoms after consuming foods containing SSL.
Food Allergies and Sensitivities: Individuals with food allergies or sensitivities may react to certain food additives, including SSL. While SSL itself is not a common allergen, it may be derived from ingredients such as milk or soy, which are common allergens. Individuals with known allergies or sensitivities to milk or soy should exercise caution when consuming foods containing SSL and carefully read food labels.
Cardiovascular Health: SSL is derived from stearic acid, a type of saturated fatty acid found in various food sources. While moderate consumption of saturated fats is generally considered acceptable, excessive intake of saturated fats may contribute to elevated cholesterol levels and increase the risk of cardiovascular diseases such as heart disease and stroke. However, the contribution of SSL specifically to cardiovascular health is not well-studied.
Metabolic Disorders: Some research suggests that certain food additives, including SSL, may have potential impacts on metabolic health, including glucose metabolism and insulin sensitivity. However, the specific effects of SSL on metabolic disorders such as diabetes or metabolic syndrome are not well-established and require further research.
Inflammatory Conditions: SSL is generally considered safe for consumption and is not typically associated with inflammatory conditions. However, individuals with conditions characterized by chronic inflammation, such as rheumatoid arthritis or inflammatory bowel disease, may benefit from minimizing their intake of processed foods containing additives like SSL.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | -0.6 | |
Acne | 0.3 | 2 | -5.67 |
ADHD | 0.9 | 2.7 | -2 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.5 | -0.67 |
Allergic Rhinitis (Hay Fever) | 0.7 | 0.6 | 0.17 |
Allergies | 2.8 | 1.2 | 1.33 |
Allergy to milk products | 1 | 0.6 | 0.67 |
Alopecia (Hair Loss) | 1.3 | 1.3 | |
Alzheimer's disease | 0.9 | 5.1 | -4.67 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 1.1 | 0.64 |
Ankylosing spondylitis | 2.2 | 1.5 | 0.47 |
Anorexia Nervosa | 0.5 | 3.1 | -5.2 |
Asthma | 1.2 | 1.2 | 0 |
Atherosclerosis | 0.9 | -0.9 | |
Atrial fibrillation | 1.9 | 0.8 | 1.37 |
Autism | 3.3 | 3.7 | -0.12 |
benign prostatic hyperplasia | 0.2 | -0.2 | |
Bipolar Disorder | 2.7 | 2.3 | 0.17 |
Brain Trauma | 0.9 | 0.2 | 3.5 |
Breast Cancer | 0.9 | 0.9 | |
Carcinoma | 0.5 | 1.1 | -1.2 |
Celiac Disease | 1.9 | 1.6 | 0.19 |
Cerebral Palsy | 0.8 | 1.1 | -0.38 |
Chronic Fatigue Syndrome | 1.2 | 1.3 | -0.08 |
Chronic Kidney Disease | 2.7 | -2.7 | |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.3 | 0 |
Chronic Urticaria (Hives) | 0.8 | 0.2 | 3 |
Coagulation / Micro clot triggering bacteria | 0.5 | 1.4 | -1.8 |
Colorectal Cancer | 1.2 | 0.9 | 0.33 |
Constipation | 1.6 | 0.3 | 4.33 |
Coronary artery disease | 1.3 | 1.9 | -0.46 |
COVID-19 | 2.3 | 4.8 | -1.09 |
Crohn's Disease | 3 | 4.1 | -0.37 |
cystic fibrosis | 0.2 | -0.2 | |
deep vein thrombosis | 0.8 | -0.8 | |
Depression | 3.6 | 3.9 | -0.08 |
Dermatomyositis | 0.9 | 0.3 | 2 |
Eczema | 0.5 | 0.7 | -0.4 |
Endometriosis | 0.7 | 1 | -0.43 |
Eosinophilic Esophagitis | 0.8 | -0.8 | |
Epilepsy | 2.2 | 1.5 | 0.47 |
erectile dysfunction | 0.7 | 0.7 | |
Fibromyalgia | 1.4 | 1.2 | 0.17 |
Functional constipation / chronic idiopathic constipation | 2.8 | 1.5 | 0.87 |
gallstone disease (gsd) | 0.7 | 0.2 | 2.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.6 | 0.33 |
Generalized anxiety disorder | 0.3 | 0.3 | 0 |
giant cell arteritis | 0.5 | 0.2 | 1.5 |
Glioblastoma | 0.6 | 0.7 | -0.17 |
Gout | 1.2 | -1.2 | |
Graves' disease | 0.2 | 2.9 | -13.5 |
Halitosis | 0 | 0.9 | 0 |
Hashimoto's thyroiditis | 2.1 | 0.2 | 9.5 |
Hidradenitis Suppurativa | 1 | -1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.7 | -0.4 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.6 | -2 |
hyperglycemia | 0.5 | 0.2 | 1.5 |
hypersomnia | 0.2 | -0.2 | |
hypertension (High Blood Pressure | 1.3 | 3.6 | -1.77 |
Hypothyroidism | 0.2 | 1.7 | -7.5 |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 1.6 | 0.2 | 7 |
Inflammatory Bowel Disease | 1 | 2.2 | -1.2 |
Insomnia | 0.9 | 1.1 | -0.22 |
Intelligence | 1.9 | 1.9 | |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 3.2 | 2.3 | 0.39 |
Juvenile idiopathic arthritis | 0.3 | -0.3 | |
Liver Cirrhosis | 2.1 | 1.4 | 0.5 |
Long COVID | 4.4 | 4.6 | -0.05 |
Low bone mineral density | 0.3 | 1 | -2.33 |
Lung Cancer | 0.2 | 1.4 | -6 |
ME/CFS with IBS | 0.2 | 0.2 | |
ME/CFS without IBS | 0.8 | 0.2 | 3 |
Metabolic Syndrome | 2.9 | 5.7 | -0.97 |
Mood Disorders | 5.9 | 5.6 | 0.05 |
multiple chemical sensitivity [MCS] | 0.2 | -0.2 | |
Multiple Sclerosis | 1.4 | 3.1 | -1.21 |
Multiple system atrophy (MSA) | 0.2 | -0.2 | |
myasthenia gravis | 0.2 | 0.5 | -1.5 |
Neuropathy (all types) | 1 | 0.2 | 4 |
neuropsychiatric disorders (PANDAS, PANS) | 1.3 | -1.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 2.7 | -0.13 |
Obesity | 3.3 | 4.5 | -0.36 |
obsessive-compulsive disorder | 0.9 | 2 | -1.22 |
Osteoarthritis | 0.7 | 0.3 | 1.33 |
Osteoporosis | 0.2 | 1.4 | -6 |
Parkinson's Disease | 2.1 | 5.1 | -1.43 |
Polycystic ovary syndrome | 1.3 | 1.2 | 0.08 |
Postural orthostatic tachycardia syndrome | 0.3 | 0.2 | 0.5 |
Premenstrual dysphoric disorder | 0.3 | 0.3 | 0 |
primary biliary cholangitis | 0.7 | 0.7 | |
Psoriasis | 1.2 | 1.1 | 0.09 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.5 | 3.3 | 0.06 |
Rosacea | 0.2 | 0.6 | -2 |
Schizophrenia | 3.1 | 3.2 | -0.03 |
scoliosis | 1.3 | 1.3 | |
sensorineural hearing loss | 0.5 | -0.5 | |
Sjögren syndrome | 1.2 | 2.1 | -0.75 |
Sleep Apnea | 0.6 | 0.7 | -0.17 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | -1.4 | |
Stress / posttraumatic stress disorder | 0.7 | 1.8 | -1.57 |
Systemic Lupus Erythematosus | 2.1 | 4 | -0.9 |
Tic Disorder | 0.9 | 0.8 | 0.13 |
Type 1 Diabetes | 1.9 | 1.9 | 0 |
Type 2 Diabetes | 2.6 | 4 | -0.54 |
Ulcerative colitis | 3.1 | 3.2 | -0.03 |
Unhealthy Ageing | 1.4 | 0.5 | 1.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.